https://www.xiconicpharma.com/contactus daily 0.75 2020-11-16 https://www.xiconicpharma.com/whatwedo daily 0.75 2020-08-19 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3da71fdd8e181c51815435/1597876023684/ What we do... - What we do… Advance life by advancing cancer therapies. https://www.xiconicpharma.com/whywedoit daily 0.75 2020-11-13 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f36fbfdfa20976266a26d32/1597440527536/ Why we do it... - Why we do it… To bring hope to patients with hard to treat cancers by providing therapies with “first-in-class” technologies in advanced antibody drug conjugates (ADCs) targeting actM. https://www.xiconicpharma.com/home daily 1.0 2020-11-24 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/5faecfd603633f0646b39822/5faf6b0e9d5601577095e0e9/1605331731476/ Home https://static1.squarespace.com/static/5f35cfc063401e503efa3414/5faecfd603633f0646b39822/5faf2b79f8f3f14190aab328/1605315452322/ Home https://static1.squarespace.com/static/5f35cfc063401e503efa3414/5faecfd603633f0646b39822/5faf2dd3ff73a225b2984ce0/1605316057422/ Home https://static1.squarespace.com/static/5f35cfc063401e503efa3414/5faecfd603633f0646b39822/5faed14124c06f5373b06f16/1605292387437/Second+Science.png Home https://www.xiconicpharma.com/science daily 0.75 2020-11-13 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3e970d54f6d623a05a8f89/1597937429935/image.jpg The Science - Matriptase serine protease activation is tightly regulated by complex formation with hepatocyte growth factor activator inhibitor-1 (HAI-1) Acidic and hypoxic conditions of tumor microenvironment can activate matriptase (actM) An imbalance in matriptase/HAI-1 ratio is observed in high-grade ovarian and prostate cancers In mice, inhibition of actM by HAI-1 overexpression inhibits tumor progression Overexpression of matriptase is evident in wide range of human epithelial tumors and B-cell lymphomas Breast, lung, prostate, gastric, ovarian, colorectal, uterine, mantle cell lymphoma and others High expression correlates with high malignancy grade and poor overall prognosis First-in-class ADC targeting cell-surface protease may be ideal tumor eradication strategy M69 mAb precisely targets actM followed by internalization and selective killing of tumor cells ActM expression almost exclusively on tumor cells, not surrounding stromal cells, at every stage of carcinogenesis Potential to inhibit multiple tumor pathways that perpetuate tumor progression Sources: Benaud Eur J Biochem 2001; Oberst Am J Path 2001; Oberst Clin Cancer Res 2002 Saleem Cancer Epidemiol Biomarkers Prev 2006; List Genes Dev 2005 Illustration: Lee AJP Cell Physio 2007 Note: M69 mAb binds only activated and not latent matriptase https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3d9ef89b525f44dbf4fe55/1597873925318/Second+Science.png The Science - ActM engages multiple substrates that can drive tumor invasiveness and metastasis when activated Protease activity promotes extracellular matrix degradation Activation of urokinase-type plasminogen activator (uPA) Degradation of fibronectin and laminin Hepatocyte growth factor (HGF) activates signaling pathways that stimulate proliferation and invasiveness through c-Met receptor Protease-activated receptor (PAR-2) activation enhances cell proliferation and migration Illustrations: Lee J Cancer Molecules 2006 https://www.xiconicpharma.com/who-we-are daily 0.75 2020-11-20 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3c1352af07740203b9156e/1597772662006/About+us.png Who we are... - Who we are… Xiconic Pharmaceuticals was founded in 2016 to advance a key discovery by Dr. Joseph Bertino and was formed as a Delaware corporation in 2019. Dr. Bertino and colleagues discovered a novel tumor antigen known as activated matriptase (actM) that is overexpressed almost exclusively on tumor cells and could lead to the development of treatments for various cancer indications. Xiconic’s lead compound, XCN-010, is a Matriptimab™-MMAE antibody-drug conjugate targeting human actM. Xiconic has licensed key XCN-010 intellectual property from Rutgers and Georgetown universities. Compelling preclinical data in cancer models supports clinical development for multiple indications. https://www.xiconicpharma.com/strategic-partners daily 0.75 2020-08-20 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3c0ad59dcb620203fada23/1597951237837/Georgetown2.png Strategic Partners https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5f3c096d4a22ef7e790c0ddc/1597951223345/Rutgers.png Strategic Partners https://www.xiconicpharma.com/board-of-directors daily 0.75 2021-10-21 https://www.xiconicpharma.com/management-team daily 0.75 2021-10-21 https://www.xiconicpharma.com/board-of-directors-all-directors daily 0.75 2020-08-21 https://www.xiconicpharma.com/products daily 0.75 2020-11-21 https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5faef9d754d01722c1a69df0/1605304868698/Third+Science.png XCN-010 - First-in-class antibody target: Activated matriptase (actM) A highly cancer-specific antigen overexpressed on multiple epithelial tumors and certain lymphomas(1) Participates with multiple drivers of tumor invasiveness and metastases(2) Proprietary PEGylation technology(3) improves linker characteristics Reduces potential for off-target toxicities(4) Decreases hydrophobicity and aggregation Facilitates efficient intracellular drug release Preserves core moiety used in FDA-approved ADCs Stable in circulation; intracellular cleavage by cathepsin B Broadly cytotoxic payload and DAR Monomethyl auristatin E (MMAE), a potent microtubule inhibitor used in three FDA-approved ADCs(5) Drug antibody ratio of 3.5 MMAE/mAb accepted by FDA https://static1.squarespace.com/static/5f35cfc063401e503efa3414/t/5faef09f9d5601577085c360/1605300395628/Fourth+Science.png XCN-010 https://www.xiconicpharma.com/terms-of-use daily 0.75 2020-11-19 https://www.xiconicpharma.com/cookies-policy daily 0.75 2020-11-19 https://www.xiconicpharma.com/xiconic-pharmaceuticals-llc-privacy-policy daily 0.75 2020-11-19